Faecal immunochemical test (FIT) based prioritisation of new patient symptomatic cases referred for colorectal investigation
New Zealand Medical Journal · 2024
DOI: 10.26635/6965.6582 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Zealand Medical Journal, 2024. Verfasst von James Falvey und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterologist, Department of Gastroenterology, Christchurch Hospital, Canterbury. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonoscopy, Referral and Consultation, Occult Blood. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
aim: Quantitative faecal haemoglobin (fHb) measurement by faecal immunochemical test (FIT) is a powerful biomarker for colorectal cancer (CRC) and is incorporated in referral, prioritisation and triage protocols for symptomatic cases in other countries. We report our use of FIT to prioritise new patient symptomatic cases referred for colorectal investigation. method: Cases referred for investigation of new colorectal symptoms who were aged ≥50 years (≥40 years Māori/Pacific peoples), who would otherwise be triaged to non-urgent colonoscopy, were asked to provide a stool sample for FIT. Following FIT testing, cases were re-triaged to either urgent colonoscopy, non-urgent colonoscopy or computed tomography colonography (CTC) depending on fHb concentration (measured in micrograms haemoglobin per gram of stool [mcg/g]) and incorporating clinical judgement. At pathway initiation, cases already waiting for colonoscopy on the non-urgent new patient waiting list were approached first, and then new patient (NP) referrals for colonoscopy could be triaged to the pathway at the discretion of the triaging consultant. results: Out of 739 cases, 715 (97%) returned FIT samples, and 691 cases completed colorectal investigations. Overall FIT positivity ≥10mcg/g was 17.1%. Fifteen colorectal cancers (CRC) were detected (2.2%). The sensitivity and specificity of FIT ≥10mcg/g for CRC were 80.0% (54.0–93.7%) and 84.3 (81.4–86.9%) respectively. A total of 432 cases (62.5%) completed the pathway without recourse to colonoscopy, and the median time to CRC diagnosis for NP from referral was 25 days. conclusion: FIT based prioritisation of cases referred with symptoms concerning for CRC is feasible and reduces time to CRC diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gastroenterologist, Department of Gastroenterology, Christchurch Hospital, Canterbury.
- Professor of Medicine, University of Otago/Christchurch; Clinical Director of Gastroenterology, Department of Gastroenterology, Christchurch Hospital, Christchurch.
- Radiologist, Department of Radiology, Christchurch Hospital, Christchurch.
- Scientific Officer, Canterbury Health Laboratories, Christchurch Hospital, Christchurch.
- General Practitioner, Department of Gastroenterology, Christchurch Hospital, Christchurch.
Zitieren
APA
Falvey, J., Stedman, C. M., Dunn, J., Sies, C., & Levin, S. (2024). Faecal immunochemical test (FIT) based prioritisation of new patient symptomatic cases referred for colorectal investigation. New Zealand Medical Journal. https://doi.org/10.26635/6965.6582
Vancouver
Falvey J, Stedman CM, Dunn J, Sies C, Levin S. Faecal immunochemical test (FIT) based prioritisation of new patient symptomatic cases referred for colorectal investigation. New Zealand Medical Journal. 2024. doi:10.26635/6965.6582
BibTeX
@article{Falvey2024,
author = {Falvey, James and Stedman, Catherine M and Dunn, Joel and Sies, Chris and Levin, Susan},
title = {Faecal immunochemical test (FIT) based prioritisation of new patient symptomatic cases referred for colorectal investigation},
journal = {New Zealand Medical Journal},
year = {2024},
doi = {10.26635/6965.6582}
}
EUVIMED